Ligand validation:6RMY

V14: 3-(cyclooctylamino)-2,5,6-trifluoro-4-[(2-hydroxyethyl)sulfonyl]benzenesulfonamide

V14 is a Ligand Of Interest in 6RMY designated by the Author

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
6RMY_V14_A_302	93%	9%	0.077	0.973	2.48	2.07	9	6	1	0	100%	1
6QL3_V14_A_302	98%	8%	0.068	0.987	2.63	2.1	4	9	1	0	100%	1
4Q07_V14_A_303	98%	25%	0.071	0.99	1.62	1.44	4	4	0	0	100%	0.5
4Q09_V14_A_302	97%	18%	0.074	0.987	1.47	2.02	3	11	0	0	100%	1
7NZT_V14_A_304	94%	22%	0.088	0.986	1.47	1.74	4	10	0	0	100%	1
4PYY_V14_A_302	48%	5%	0.173	0.915	2.47	2.78	5	9	2	0	100%	0.5
6FE1_V14_A_302	87%	5%	0.099	0.97	3.12	2.33	8	9	0	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.